ClinicalTrials.gg
Active, not recruitingNCT04703829Updated Oct 27, 2026Results posted

Virtual Incision Robotically Assisted Surgical Device Use in Minimally Invasive Colectomy

An interventional study of VI-RASD use in minimally invasive right or left colectomy and Right or Left colectomy in Colon Cancer, Colon Polyp and Diverticular Diseases, sponsored by Virtual Incision Corporation. Active, not recruiting at 3 sites in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Virtual Incision Corporation · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now Active, not recruitingResults posted+11 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Enrollment
550th of 865
30 · median 50
Started
2021
with 39 others
No phase
264 of 1,123
29 open now
Primary completion
2023-02
later than 7 of 187 live
Registered
908th of 1,123
by date

Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 550th largest by enrollment of the 865 interventional ones that give a count, is one of 40 that started in 2021, is one of 264 with no phase, reaches primary completion later than 7 of the 187 other live ones, and was the 908th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,123 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

For patients with colon polyps (clumps of cells in the lining of the colon) treatment often requires removal of the affected portion of the colon. Both conventional laparoscopic and robotically assisted minimally invasive surgery have been shown to have reduced complication rates and shorter hospital stays.

This study aims to look at the use of the VI RASD as a robotic surgical device in right or left colectomy procedures to see if the device performs as intended and is safe for use.

Read the detailed description

The purpose of the clinical study is to evaluate the device's indications for use in the clinical environment. The VI RASD is a surgical tool intended to assist in the endoscopic manipulation of tissue during bowel resections. The VI RASD is designed to allow a surgeon to perform minimally invasive colon procedures in the same fashion used in laproscopic and robotically assisted surgery with a single incision site in the abdominal wall.

The study will evaluate the efficacy of the VI RASD in manipulating and dissecting the right or left colon and preparing the colon for resection. The safety profile of the device will also be assessed through analysis of overall intraoperative and post operative adverse events as compared to published literature.

03

Conditions studied

  • Colon Cancer
  • Colon Polyp
  • Diverticular Diseases
  • Inflammatory Bowel Diseases

Keywords

  • Colectomy
04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is able to provide
  • 22-85 years of age
  • No history of frozen abdomen due to abdominal adhesions or multiple previous bowel obstructions
  • (BMI) between 19.5- 45 kg/m2
  • A weight of at least 100 lbs. (45.36 kg.).
  • Height of at least 60 inches (152 cm)
  • ASA grades I through III
  • Available for required postoperative follow up visits at 14 days and 30 days

Exclusion criteria

Exclusion Criteria:

  • Subject unable or unwilling to provide
  • Under the age of 22 or greater than the age of 85 years
  • Has polyps that can be completely removed with negative surgical margins by colonoscopy.
  • Has Stage T4 cancer diagnosis
  • History of abdominal adhesions or bowel obstruction
  • of \< 19.5 and > 45 kg/m2
  • Heights \< 60 inches
  • ASA grades IV-VI
  • End stage renal disease
  • Liver Cirrhosis
  • Women who are pregnant or lactating
  • Active infection or has a history of local or systemic infection within 30 days of study screening
  • Has had major surgery within 30 days prior to study enrollment or is scheduled to have major surgery within 30 days
  • Has participated or is participating in another clinical study which may confound study results
  • In the opinion of the Investigator, patient is not likely to comply with the required protocol activities; or, has a medical condition that should exclude the patient from the study
  • \< 8.0
  • Not currently coagulopathic
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    VI-RASD

    Use of VI RASD in right or left colectomy procedures

    Device: VI-RASD use in minimally invasive right or left colectomy · Procedure: Right or Left colectomy

Interventions

  • DeviceVI-RASD use in minimally invasive right or left colectomy

    Virtual Incision Corp, VI-RASD use in right or left colectomy procedures.

  • ProcedureRight or Left colectomy

    Surgical Procedures in which the VI RASD will be used.

06

What researchers measure

Primary outcomes

  1. Efficacy: Number of Participants With Successful Completion of the VI RASD Steps in Colectomy Procedures Without Conversion to Open Surgery

    Count and calculated percentage of enrolled subjects in which the VI RASD steps were successfully completed and did not require conversion to open surgery. VI RASD steps include: the VI-RASD system is inserted and deployed to corresponding abdominal cavity, used to manipulate and dissect the colon allowing for transection of the colon and small bowel, and system is removed from the abdominal cavity.

    Time frame: Intraoperative Period- Surgical Procedure Start time to Surgical Procedure End time

  2. Determine the Safety Profile of VI-RASD as the Number of Enrolled Subjects Experiencing Either an Intraoperative and/or Postoperative Adverse Events Occurring Within 30 Days Post Procedure.

    Count and calculated percentage of enrolled subjects experiencing an intraoperative and/or postoperative adverse events.

    Time frame: Time insertion of the VI RASD device is initiated (intraoperative) through 30 days (+/- 5 days) post procedure (post operative).

Secondary outcomes

  1. Clinical Outcome Measure- Length of Stay (Number of Days)

    Median number of days for the VI-RASD arm calculated from Date of Procedure (Day 0) to Date of Discharge.

    Time frame: Calculated in number of days from date of procedure through date of discharge

  2. Clinical Outcome Measures-Number of Subjects With Reported Intraoperative Adverse Event

    Comparison of number/calculated percentage of enrolled subjects experiencing an intraoperative adverse event.

    Time frame: Intraoperative-Procedure start time to Procedure end time

  3. Clinical Outcome Measure- Number of Participants Requiring Conversion to Open Surgery

    Count and calculated percentage of enrolled subjects requiring conversion to open surgery.

    Time frame: Intraoperative: Procedure start time to Procedure end time

  4. Clinical Outcome Measure-Median Operative Time for All Enrolled Participants.

    Median time(all enrolled participants) in minutes elapsed between procedure start and stop time.

    Time frame: Intraoperative: Procedure Start Time to Procedure End Time

  5. Clinical Outcome Measure-Number of Subjects With Reported Post Operative Complications Related to Study Device and/or Procedure.

    Comparison of Number/Calculated percentage of participants with a reported adverse event related to the study device and/or procedure that occurred post operatively thru the 30 day post procedure visit.

    Time frame: Procedure end time thru 30 day post procedure visit

  6. Clinical Outcome Measure-Re-admission Rate: Number of Participants Readmitted to Hospital

    Number/calculated percentage of participants readmitted to the hospital after discharge from study procedure for any reason.

    Time frame: From date of discharge thru 30 days post procedure

  7. Clinical Outcome Measure- Re Encounter Rates-Number of Participants Requiring an Unplanned Visit.

    Number/Calculated Percentage of participants requiring an unplanned follow up visit for a potential complication related to procedure. Unplanned visit defined as either a phone call with medical provider or a visit to a medical provider.

    Time frame: From date of discharge thru 30 days post procedure

  8. Clinical Outcome Measure-Reoperation Rate: Number of Participants Requiring Reoperation

    Total number/calculated percentage of subjects requiring any additional operation related to the underlying medical condition. This number is compared to Published literature Zawadski PMID 31481637

    Time frame: From date of procedure thru 30 day post procedure.

  9. Clinical Outcome Measure-Reoccurrence Rate: Number of Participants With Recurrence of Disease

    Number of subjects reporting recurrence of underlying medical condition/indication for for colectomy procedure. No comparative data is available in published literature referenced in the study.

    Time frame: From date of procedure thru 30 days post procedure.

  10. Clinical Outcome Measure- Mortality: Number of Deaths Reported

    Number and calculated percentage of all cause deaths.

    Time frame: From date of procedure through 30 day post procedure

  11. Clinical Outcome Measure- Number of Additional Laparoscopic Ports Used, Including Reason for Use.

    Number of additional laparoscopic ports used during procedure was collected. Reason for additional port also captured.

    Time frame: Intraoperative

Other outcomes

  1. Long Term Oncological Status

    Annual assessment of cancer status (Active-with/without treatment, metastasized, remission).

    Time frame: Date of procedure through 5 years post procedure

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneVI-RASD
Started30
Completed30
Not completed0

Outcome measures

PrimaryEfficacy: Number of Participants With Successful Completion of the VI RASD Steps in Colectomy Procedures Without Conversion to Open Surgery

Count and calculated percentage of enrolled subjects in which the VI RASD steps were successfully completed and did not require conversion to open surgery. VI RASD steps include: the VI-RASD system is inserted and deployed to corresponding abdominal cavity, used to manipulate and dissect the colon allowing for transection of the colon and small bowel, and system is removed from the abdominal cavity.

Time frame:
Intraoperative Period- Surgical Procedure Start time to Surgical Procedure End time
Reported as:
Count of participants · Participants
Efficacy: Number of Participants With Successful Completion of the VI RASD Steps in Colectomy Procedures Without Conversion to Open Surgery
ParticipantsVI-RASD
Primary dissection completed with VI RASD30
Conversion to Open surgery0
Statistical analysis
  • VI-RASD ·
PrimaryDetermine the Safety Profile of VI-RASD as the Number of Enrolled Subjects Experiencing Either an Intraoperative and/or Postoperative Adverse Events Occurring Within 30 Days Post Procedure.

Count and calculated percentage of enrolled subjects experiencing an intraoperative and/or postoperative adverse events.

Time frame:
Time insertion of the VI RASD device is initiated (intraoperative) through 30 days (+/- 5 days) post procedure (post operative).
Reported as:
Count of participants · Participants
Determine the Safety Profile of VI-RASD as the Number of Enrolled Subjects Experiencing Either an Intraoperative and/or Postoperative Adverse Events Occurring Within 30 Days Post Procedure.
ParticipantsVI-RASD
Intraoperative complications0
Post operative complications10
Statistical analysis
  • VI-RASD ·
SecondaryClinical Outcome Measure- Length of Stay (Number of Days)

Median number of days for the VI-RASD arm calculated from Date of Procedure (Day 0) to Date of Discharge.

Time frame:
Calculated in number of days from date of procedure through date of discharge
Reported as:
Mean · Days
Clinical Outcome Measure- Length of Stay (Number of Days)
DaysVI-RASD
Clinical Outcome Measure- Length of Stay (Number of Days)3.6 (2 to 26)
SecondaryClinical Outcome Measures-Number of Subjects With Reported Intraoperative Adverse Event

Comparison of number/calculated percentage of enrolled subjects experiencing an intraoperative adverse event.

Time frame:
Intraoperative-Procedure start time to Procedure end time
Reported as:
Count of participants · Participants
Clinical Outcome Measures-Number of Subjects With Reported Intraoperative Adverse Event
ParticipantsVI-RASD
Device Related0
Procedure Related0
SecondaryClinical Outcome Measure- Number of Participants Requiring Conversion to Open Surgery

Count and calculated percentage of enrolled subjects requiring conversion to open surgery.

Time frame:
Intraoperative: Procedure start time to Procedure end time
Reported as:
Count of participants · Participants
Clinical Outcome Measure- Number of Participants Requiring Conversion to Open Surgery
ParticipantsVI-RASD
Clinical Outcome Measure- Number of Participants Requiring Conversion to Open Surgery0
SecondaryClinical Outcome Measure-Median Operative Time for All Enrolled Participants.

Median time(all enrolled participants) in minutes elapsed between procedure start and stop time.

Time frame:
Intraoperative: Procedure Start Time to Procedure End Time
Reported as:
Median · minutes
Clinical Outcome Measure-Median Operative Time for All Enrolled Participants.
minutesVI-RASD
Clinical Outcome Measure-Median Operative Time for All Enrolled Participants.146 (80 to 309)
SecondaryClinical Outcome Measure-Number of Subjects With Reported Post Operative Complications Related to Study Device and/or Procedure.

Comparison of Number/Calculated percentage of participants with a reported adverse event related to the study device and/or procedure that occurred post operatively thru the 30 day post procedure visit.

Time frame:
Procedure end time thru 30 day post procedure visit
Reported as:
Count of participants · Participants
Clinical Outcome Measure-Number of Subjects With Reported Post Operative Complications Related to Study Device and/or Procedure.
ParticipantsVI-RASD
Clinical Outcome Measure-Number of Subjects With Reported Post Operative Complications Related to Study Device and/or Procedure.10
SecondaryClinical Outcome Measure-Re-admission Rate: Number of Participants Readmitted to Hospital

Number/calculated percentage of participants readmitted to the hospital after discharge from study procedure for any reason.

Time frame:
From date of discharge thru 30 days post procedure
Reported as:
Count of participants · Participants
Clinical Outcome Measure-Re-admission Rate: Number of Participants Readmitted to Hospital
ParticipantsVI-RASD
Clinical Outcome Measure-Re-admission Rate: Number of Participants Readmitted to Hospital0
SecondaryClinical Outcome Measure- Re Encounter Rates-Number of Participants Requiring an Unplanned Visit.

Number/Calculated Percentage of participants requiring an unplanned follow up visit for a potential complication related to procedure. Unplanned visit defined as either a phone call with medical provider or a visit to a medical provider.

Time frame:
From date of discharge thru 30 days post procedure
Reported as:
Count of participants · Participants
Clinical Outcome Measure- Re Encounter Rates-Number of Participants Requiring an Unplanned Visit.
ParticipantsVI-RASD
Clinical Outcome Measure- Re Encounter Rates-Number of Participants Requiring an Unplanned Visit.5
SecondaryClinical Outcome Measure-Reoperation Rate: Number of Participants Requiring Reoperation

Total number/calculated percentage of subjects requiring any additional operation related to the underlying medical condition. This number is compared to Published literature Zawadski PMID 31481637

Time frame:
From date of procedure thru 30 day post procedure.
Reported as:
Count of participants · Participants
Clinical Outcome Measure-Reoperation Rate: Number of Participants Requiring Reoperation
ParticipantsVI-RASDPublished Literature: Zawadzki
Clinical Outcome Measure-Reoperation Rate: Number of Participants Requiring Reoperation151
SecondaryClinical Outcome Measure-Reoccurrence Rate: Number of Participants With Recurrence of Disease

Number of subjects reporting recurrence of underlying medical condition/indication for for colectomy procedure. No comparative data is available in published literature referenced in the study.

Time frame:
From date of procedure thru 30 days post procedure.
Reported as:
Count of participants · Participants
Clinical Outcome Measure-Reoccurrence Rate: Number of Participants With Recurrence of Disease
ParticipantsVI-RASD
Clinical Outcome Measure-Reoccurrence Rate: Number of Participants With Recurrence of Disease0
SecondaryClinical Outcome Measure- Mortality: Number of Deaths Reported

Number and calculated percentage of all cause deaths.

Time frame:
From date of procedure through 30 day post procedure
Reported as:
Count of participants · Participants
Clinical Outcome Measure- Mortality: Number of Deaths Reported
ParticipantsVI-RASD
Clinical Outcome Measure- Mortality: Number of Deaths Reported0
SecondaryClinical Outcome Measure- Number of Additional Laparoscopic Ports Used, Including Reason for Use.

Number of additional laparoscopic ports used during procedure was collected. Reason for additional port also captured.

Time frame:
Intraoperative
Reported as:
Number · number of participants
Clinical Outcome Measure- Number of Additional Laparoscopic Ports Used, Including Reason for Use.
number of participantsVI-RASD
Requiring one additional port19
Requiring two additional ports11
Requiring 3 additional ports0
Reason for additional port:additional tools30
Reason for additional port : Insufflation2
Other pre-specifiedLong Term Oncological Status

Annual assessment of cancer status (Active-with/without treatment, metastasized, remission).

Time frame:
Date of procedure through 5 years post procedure

Results for this outcome have not been posted.

Adverse events

Collected over Time insertion of the VI RASD device is initiated through 30 days post procedure, approximately one month.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VI-RASD-EXPECTED EVENTS0/30 (0%)3/30 (10%)30/30 (100%)
VI RASD -UNEXPECTED EVENTS0/30 (0%)0/30 (0%)0/30 (0%)
Most frequent serious events
Most frequent serious events
EventVI-RASD-EXPECTED EVENTSVI RASD -UNEXPECTED EVENTS
Anastomotic haemorrhageInjury, poisoning and procedural complications1/30—
AnemiaBlood and lymphatic system disorders1/30—
Blood Loss AnemiaVascular disorders1/30—
Pelvic AbcessInfections and infestations1/30—
Gastointestinal Anastomotic LeakGastrointestinal disorders1/30—
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/30—
Septic ShockVascular disorders1/30—
Most frequent other events
Most frequent other events
EventVI-RASD-EXPECTED EVENTSVI RASD -UNEXPECTED EVENTS
Incision site painGeneral disorders20/30—
Procedural PainGeneral disorders10/30—
RashSkin and subcutaneous tissue disorders2/30—

Baseline characteristics

Subjects undergoing Colectomy procedures using the VI-RASD.

Age, Categorical
Age, Categorical(Participants)VI-RASD
<=18 years0
Between 18 and 65 years17
>=65 years13
Age, Continuous
Age, Continuous(years)VI-RASD
Mean59.4 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)VI-RASD
Female13
Male17
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VI-RASD
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White28
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)VI-RASD
United States30
Body Mass Index Classification
Body Mass Index Classification(Participants)VI-RASD
Normal, 18.5-24.9 kg/m29
Overweight, 25.0-29.9 kg/m213
Obese, ≥30kg/m28
08

Study locations

3 sites
  • Bryan Medical Center
    Lincoln, Nebraska 68506, United States
  • Lankeanu Medical Center
    Wynnewood, Pennsylvania 19096, United States
  • Roper Saint Francis Mount Pleasant
    Mt. Pleasant, South Carolina 29466, United States
09

References and documents

Publications

  • Marks JH, Keller DS, Lagares-Garcia JA, Schoonyoung HP, Farritor SM, Oleynikov D, Jobst MA. Safety and Efficacy of a Novel Miniaturized Robotic-Assisted Surgery System in Colectomy: A Prospective, Investigational Device Exemption Clinical Study Using the IDEAL Framework. Dis Colon Rectum. 2024 Aug 1;67(8):1085-1093. doi: 10.1097/DCR.0000000000003249. Epub 2024 Jul 13. PubMed 38653496 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Feb 2023, 18 months.

Results were first posted in Oct 2026, 3 years 7 months after primary completion. A results delay was requested in Feb 2024.

Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2020
First posted
Jan 11, 2021
StartActual
Aug 9, 2021
Primary completionActual
Feb 15, 2023
CompletionEst.
Jan 2028
Results delay requested
Feb 16, 2024
Results first posted
Oct 1, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Withheld→Active, not recruiting
changed Oct 1, 2026
Results
Results posted, then revised
posted Oct 1, 2026 · revised Oct 27, 2026
Sites
3 sites added — first site in United States
Show 3 added (3 United States)
  • Bryan Medical Center · Lincoln, United States
  • Lankeanu Medical Center · Wynnewood, United States
  • Roper Saint Francis Mount Pleasant · Mt. Pleasant, United States
Oct 1, 2026
Start date
Set to Aug 9, 2021 (actual)
Oct 1, 2026
Primary completion
Set to Feb 15, 2023 (actual)
Oct 1, 2026
Study completion
Set to Jan 2028
Oct 1, 2026
Eligibility
Revised
Oct 1, 2026
Interventions
Arms or interventions changed
Oct 1, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38653496 ↗
Oct 1, 2026
Title
[Trial of device that is not approved or cleared by the U.S. FDA]→Virtual Incision Robotically Assisted Surgical Device Use in Minimally Invasive Colectomy
Oct 1, 2026
Sponsor
[Redacted]→Virtual Incision Corporation
Oct 1, 2026
Show all 2 updates
  1. Oct 27, 2026
    Posted results revised
    + 1 other change: verification date
  2. Oct 1, 2026
    Withheld→Active, not recruiting
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38653496 ↗
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • Bryan Medical Center · Lincoln, United States
    • Lankeanu Medical Center · Wynnewood, United States
    • Roper Saint Francis Mount Pleasant · Mt. Pleasant, United States
    Start date Set to Aug 9, 2021 (now actual)
    Primary completion Set to Feb 15, 2023 (now actual)
    Study completion Set to Jan 2028
    Eligibility Revised
    Interventions Arms or interventions changed
    Sponsor [Redacted]→Virtual Incision Corporation
    Title [Trial of device that is not approved or cleared by the U.S. FDA]→Virtual Incision Robotically Assisted Surgical Device Use in Minimally Invasive Colectomy
    + 9 other changes: registry dates, verification date, oversight details, description, conditions, design details, secondary outcomes, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04703829
Lead sponsor
Virtual Incision Corporation
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Aug 9, 2021
Primary completion
Feb 15, 2023
Completion
Jan 2028 (estimated)
Results posted
Oct 1, 2026
Last update
Oct 27, 2026

Study contacts

Dmitry Oleynikov, M.D.
study chair · Virtual Incision Corp.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion